Led · Series B · Oct 2022

Mindful Care delivers flexible mental healthcare including psychiatry, group therapy, and individual therapy with offerings such as MicroTherapy® and MindFit® Group Therapy. The company provides same- or next-day care and offers both at-home and in-person treatment, plus combined psychiatry-and-therapy services. It operates a Mental Health Urgent Care service for immediate needs and offers access to GeneSight, a DNA service to guide medication response. Led by Founder and CEO Dr. Tamir Aldad, Mindful Care emphasizes improving clinical outcomes and patient satisfaction through technology. The company plans to expand its current offerings into the Midwest and Southeast and to launch new individual therapy and addiction treatment programs. The recent financing will be used to support those geographic expansions, program launches, and further technology development. Mindful Care applies the urgent care model to mental health by providing same- or next-day psychiatric care, medication stabilization, group therapy, individual therapy, and telehealth options. The company operates Mental Health Urgent Care centers and offers at-home and in-person treatment, plus GeneSight DNA testing to guide medication decisions. Mindful Care works with nearly all insurance providers and offers affordable self-pay rates to increase access. To date it has helped over 20,000 patients and has opened multiple locations including an initial site in West Hempstead, NY, seven additional locations in the Greater NYC area, two in New Jersey, and two in Chicago. The company plans to use new funding to open additional urgent mental healthcare locations and expand its online solutions.

Participated · Equity · Apr 2022

Gripnr builds Web3 tabletop games and is preparing to launch its first 5E game and accompanying NFT ecosystem. Its inaugural title, The Glimmering, features a genesis NFT collection of 10,000 individual characters with hand-drawn attributes designed specifically for gameplay. Each character will carry unique rarities—classes, ancestry, skills, and background—and ongoing character data will be stored on-chain. Members who mint the genesis collection will receive immediate community benefits while on-chain play is developed. The team includes CEO Brent McCrossen, CTO Luke Ledet, creative director Kyle Mortensen, lead artist Justin Kamerer, D&D game creator Stephen Radney-MacFarland, and Patrick Comer (whose research platform Lucid was acquired for over $1 billion). Gripnr raised $2.5M to fund the launch of its first game and genesis NFT collection.

Participated · Series B · Apr 2022

ProofPilot provides StudyCoPilot, a clinical experience platform that centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. Its products and services support initiatives such as improving DE&I, streamlining recruitment and retention, and easing site burden. The system has scaled capabilities for enterprise use and has pharmaceutical clients deploying it globally. The company raised a Series C and intends to use the funds to expand operations and broaden its business reach. CEO Chris Venezia said repeat investment from Series B investors validates market need and provides resources to scale and accelerate life-saving therapies. ProofPilot is a NYC-based Software as a Service clinical trial research platform that enables users to design, launch, participate in, and manage research studies. The company provides a fully digitized platform with self-design study tools, trial process management, and remote source verification capabilities. It offers two products: ProofPilot Rx for life science companies and ProofPilot 365 for wellness interventions. ProofPilot was founded in 2014 by Matthew Amsden. The company raised over $12M in a Series B financing announced April 4, 2022. As part of the raise, investor and healthcare strategist Esther Dyson joined ProofPilot’s board of directors. ProofPilot is a New York-based startup that helps researchers design and manage scientific studies, including randomized controlled trials and outcome studies. Its platform aims to reduce systematic issues that arise during study execution and to make research more efficient. The company launched after receiving $1.85 million in investment from CueBall Capital, Brooklyn Bridge Ventures and others. Cofounder Matthew Amsden said ProofPilot was born from frustration that health and social innovations were getting lost because it was too expensive to test whether they worked. The company raised the capital in 2014, then took a brief break to further develop its technology. It has now returned with the goal of allowing researchers' work to be guided by curiosity rather than concerns about protocol. ProofPilot aims to make it easier and more efficient for professionals to run studies.

Participated · Series A · Jun 2021

Authenticx provides conversational intelligence for healthcare by analyzing millions of customer interactions (voice, chat, email) to surface actionable insights at scale. The platform is used to identify friction points and reveal hidden barriers, motivators, and strategies to improve patient experience and staff efficiency. Authenticx already supports five of the top 10 global pharmaceutical companies and produced a 2022 report after listening to 100 million conversations. The company says its technology humanizes conversational intelligence and aggregates ignored interaction data to surface transformational opportunities. The recent financing will be used to innovate machine learning, support sales and marketing, and grow the business. Authenticx is based in Indianapolis and emphasizes aligning business decisions with patient experiences. Authenticx builds a system that analyzes recorded customer calls, texts, online chats, emails and other interactions to surface actionable customer and patient insights. Its platform is aimed at healthcare and insurance organizations to improve call-center performance, reduce unnecessary calls and improve customer communications. The company was founded in August 2018 by CEO Amy Brown and is based in Carmel. Authenticx says some of the most prominent health care organizations across the country use its product, though it does not disclose clients. The new funding will be used for ongoing product development and to boost hiring. The company expects headcount to grow from fewer than 20 a year ago to about 32 by the end of June and roughly 50 by the end of the year as it scales. Authenticx provides a platform that combines existing customer interactions — including call center recorded calls, texts, chats, emails and more — into a single platform for healthcare organizations. The platform organizes and structures conversational data through a customized dashboard, enabling pharma and health-insurance customers to generate insights that inform business decisions. The software analyzes and activates customers' voices to reveal opportunities in healthcare. The company is led by Founder and CEO Amy Brown and is based in Indianapolis, Indiana. Authenticx closed an $800k equity pre-seed funding round led by M25 with participation from Elevate Ventures and Innovatemap Ventures. Victor Gutwein of M25 and Jane Niederberger of Elevate Ventures joined its board, and the company intends to use the funds to expand operations and its business reach.

Led · Series A · May 2021

RazorMetrics is an Austin, Texas-based healthcare technology company that provides a SaaS platform focused on lowering pharmacy costs for at-risk employers and health plans. The company is led by CEO and co-founder Tom Dorsett and has launched the RazorMetrics Partnership Collective. It plans program rollouts with large strategic partners in Q2 2021 with an aggregate reach of over 59,000,000 employees and members. In March 2021 RazorMetrics raised $6m in a Series A round led by Sopris Capital, with participation from individual investors Joel Trammel and Jonathan Weiner. The company intends to use the new funds to expand current operations to accommodate growth. No other financial details were disclosed in the article.